Determination of rivaroxaban in patient’s plasma samples by anti-Xa chromogenic test associated to High Performance Liquid Chromatography tandem Mass Spectrometry (HPLC-MS/MS)

Rivaroxaban is an oral direct factor Xa inhibitor, therapeutically indicated in the treatment of thromboembolic diseases. As other new oral anticoagulants, routine monitoring of rivaroxaban is not necessary, but important in some clinical circumstances. In our study a high-performance liquid chromat...

Descripción completa

Detalles Bibliográficos
Autores principales: Derogis, Priscilla Bento Matos, Sanches, Livia Rentas, de Aranda, Valdir Fernandes, Colombini, Marjorie Paris, Mangueira, Cristóvão Luis Pitangueira, Katz, Marcelo, Faulhaber, Adriana Caschera Leme, Mendes, Claudio Ernesto Albers, Ferreira, Carlos Eduardo dos Santos, França, Carolina Nunes, Guerra, João Carlos de Campos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295670/
https://www.ncbi.nlm.nih.gov/pubmed/28170419
http://dx.doi.org/10.1371/journal.pone.0171272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295670/
https://www.ncbi.nlm.nih.gov/pubmed/28170419
http://dx.doi.org/10.1371/journal.pone.0171272

Ejemplares similares